NHERF1/EBP50 Suppresses Wnt-β-Catenin Pathway–Driven Intestinal Neoplasia

Maria-Magdalena Georgescu*, Mihai Gagea† and Gilbert Cote‡

*Department of Pathology and Translational Pathobiology, Louisiana State University, Shreveport, LA, 71103, USA; †Department of Veterinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA; ‡Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

Abstract
NHERF1/EBP50, an adaptor molecule that interacts with β-catenin, YAP, and PTEN, has been recently implicated in the progression of various human malignancies, including colorectal cancer. We report here that NHERF1 acts as a tumor suppressor in vivo for intestinal adenoma development. NHERF1 is highly expressed at the apical membrane of mucosa intestinal epithelial cells (IECs) and serosa mesothelial cells. NHERF1-deficient mice show overall longer small intestine and colon that most likely could be attributed to a combination of defects, including altered apical brush border of absorptive IECs and increased number of secretory IECs. NHERF1 deficiency in ApcMin/+ mice resulted in significantly shorter animal survival due to markedly increased tumor burden. This resulted from a moderate increase of the overall tumor density, more pronounced in females than males, and a massive increase in the number of large adenomas in both genders. The analysis of possible pathways controlling tumor size showed upregulation of Wnt-β-catenin pathway, higher expression of unphosphorylated YAP, and prominent nuclear expression of cyclin D1 in NHERF1-deficient tumors. Similar YAP changes, with relative decrease of phosphorylated YAP and increase of nuclear YAP expression, were observed as early as the adenoma stages in the progression of human colorectal cancer. This study discusses a complex role of NHERF1 for intestinal morphology and presents indisputable evidence for its in vivo tumor suppressor function upstream of Wnt-β-catenin and Hippo-YAP pathways.

Neoplasia (2016) 18, 512–523

Introduction
Human colorectal cancer (CRC) is the third most common type of cancer and the third cause of mortality due to cancer in the United States [1]. It typically evolves from a benign polyp, or adenoma, to malignant carcinoma that starts in the mucosa [carcinoma in situ; American Joint Committee on Cancer (AJCC) stage 0] and spreads through the other layers of the colon or rectum. In advanced stages, malignant cells metastasize to the lymph nodes (AJCC stage III) or to distant organs (AJCC stage IV). The ability of CRC cells to invade and metastasize renders the tumors unresealtable and resistant to chemotherapy and diminishes abruptly the overall survival rate to approximately 10% at 5 years for AJCC stage IV patients [2].

The understanding of the progression of CRC sets the foundation for the development of therapeutic approaches. Approximately 85% of sporadic CRCs have deregulation of the canonical Wnt-β-catenin pathway, the same central pathway that is involved in intestinal epithelial cell (IEC) renewal [3]. Wnt3, 6, and 9B expressed only in the crypt epithelium bind to Frizzled transmembrane receptors and to low-density lipoprotein receptor–related proteins-5/6 [4]. They activate the pathway by disassembling the cytoplasmic destruction complex formed by axin, Apc, GSK-3β, CK1α/ε, and β-catenin [5,6]. In this complex, CK1 and GSK-3β phosphorylate β-catenin on N-terminal residues and target it for proteasome degradation.

Abbreviations: H&E, hematoxylin and eosin; IEC, intestinal epithelial cell; IF, immunofluorescence; IHC, immunohistochemistry; CRC, colorectal cancer; ERM, ezrin-radixin-moesin; NHERF1/EBP50, Na+/H+, exchanger binding phosphoprotein 50; PI3K, phosphoinositol 3-OH kinase; PM, plasma membrane; SI, small intestine; YAP, Yes-associated protein (also known as YAP65)

Address all correspondence to: Maria-Magdalena Georgescu, Louisiana State University, 1501 Kings Highway, Shreveport, LA, 71103.
E-mail: mmgeorgescu@yahoo.com

© 2016 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
To establish whether NHERF1 also has a role in CRC progression, we used the epithelial to mesenchymal transition, and increased migration [14,17]. In polarized colonic two-dimensional (2D) and 3D cell models leads to mouse embryonic fibroblasts [16], and its depletion from the apical PM proliferation [14]. NHERF1 suppresses the Wnt-β-catenin fronts [15]. Cytoplasmic expression of NHERF1 increases cell cytoplasm in a subset of CRCs [14] and in the nucleus in invasive CRC lost from the apical plasma membrane (PM) of IECs in tubular adenoma [14]. Interestingly, NHERF1 can be highly expressed in the cytoplasm in a subset of CRCs [14] and in the nucleus in invasive CRC fronts [15]. Cytoplasmic expression of NHERF1 increases cell proliferation [14]. NHERF1 suppresses the Wnt-β-catenin pathway in mouse embryonic fibroblasts [16], and its depletion from the apical PM in polarized colonic two-dimensional (2D) and 3D cell models leads to loss of cell polarity and gland morphology, disorganized solid growth, epithelial to mesenchymal transition, and increased migration [14,17].

To establish whether NHERF1 also has a role in vivo as modulator of CRC progression, we used the ApcMin/+ mice that constitute the most used model for CRC development [18]. ApcMin/+ mice have a point mutation in one APC allele and develop multiple intestinal neoplasia (Min) by activation of the Wnt-β-catenin pathway. Although NHERF1 deficiency by itself led only to morphological defects, such as increased intestinal length, NHERF1 deficiency in ApcMin/+ mice led to significantly shorter animal survival due to increased tumor load. The most striking difference was a marked increase in the numbers of large adenomas. The tumors from ApcMin/+ mice had reduced NHERF1 expression and activation of Wnt-β-catenin pathway. The complete lack of NHERF1 from ApcMin/+NHERF1−/− tumors induced even higher Wnt-β-catenin pathway activation, higher expression of unphosphorylated YAP, and prominent nuclear cyclin D1 expression, attesting to the important suppressor contribution of NHERF1 to Wnt-β-catenin– and YAP-driven tumorigenesis.

Materials and Methods

**Mice and Intestine Analysis**

The NHERF1-deficient mice [19] were inbred in C57BL/6J background [20] and crossed to C57BL/6J ApcMin/+ mice (The Jackson Laboratory, Bar Harbor, ME), inbred in the same C57BL/6J background. The offspring were genotyped for the NHERF1 alleles as described [19] and for the Apc alleles as indicated by the vendor. Mice at various ages were euthanized by CO2 inhalation. The entire intestinal tract was carefully dissected and measured. For tumor analysis, consensus recommendations were followed [21]. Briefly, the digestive tract was inflated and flushed with cold PBS; infused and incubated in 10% formalin for 3 hours; separated in proximal one third (duodenum and proximal jejunum), middle one third, distal one third (distal ileum), and colon; cut open longitudinally; and Swiss rolled on a paper tape with the serosa facing the tape and the proximal end in the center of the Swiss roll. Following overnight fixation in formalin and embedding, 5 levels (step sections) 0.5 mm apart were examined for each block. The numbers of neoplastic lesions, microadenomas (diameter < 1 mm), and adenomas were counted for each level, and the highest number per level was selected and scored as tumor density for each intestinal segment. The size of the tumors was measured with Leica Application Suite Version 4.3.0 software (Leica Microsystems, Switzerland) on images acquired with 2×/0.06 or 4×/0.13 objective from an Olympus BX41 microscope (Olympus America Inc., Center Valley, PA) equipped with a Leica DFC450 camera. When the adenoma was present on serial levels, the highest measurement was scored. The analysis of the intestinal lesions was performed by a certified anatomic pathologist, and the comprehensive analysis of the aged mice was performed by an experienced veterinary pathologist. The latter comprised soft tissues, such as lung, liver, kidney, spleen, stomach, and Swiss-rolled intestines, along with the decalcified osseous tissues skull, femur, and sternum.

**Human Specimens**

The frozen and formalin-fixed paraffin-embedded tissue resection specimens from patients with CRC were obtained from the Gastrointestinal Tumor Bank at MD Anderson Cancer Center (Houston, TX) and were previously described [14]. Matched sets of frozen specimens had the pathologist’s annotations as normal, deep tumor (carcinoma), and tumor edge (adenoma). Paraffin-embedded resection specimens contain areas of adenoma, carcinoma, and adjacent normal mucosa on the same slide.

**Histology, Immunohistochemistry (IHC), and Immunofluorescence (IF)**

Formalin-fixed, paraffin-embedded sections were stained with hematoxylin and eosin (H&E) and Alcian blue by using standard protocols. Mouse tissue sections were processed for IHC as described [22] by using the Histomouse-Max kit (Zymed/Invitrogen, Carlsbad, CA). Primary antibodies were applied overnight in a humidified chamber at 4°C, with washing of unbound antibodies next day in PBS for 5 minutes three times. The following primary antibodies and corresponding dilutions were used: EB50/NHERF1 1:3200 (PA1-090, ThermoFisher Scientific, Rockford, IL), β-catenin 1:300 (BD Biosciences, San Jose, CA), YAP 1:100 (4912) and P-YAP 1:2000 (13008) (Cell Signaling Technology, Danvers, MA), and cyclin D1 1:1000 (Santa Cruz Biotechnology, Santa Cruz, CA). Human tissue sections were processes for IHC as described [16]. For IF, mouse tissues were processed as for IHC, except for blockage from nonspecific binding for 30 minutes with 20% to 50% donkey serum in PBS. The NHERF1 and E-cadherin (BD Biosciences) antibodies were applied at 1:200. The secondary antibodies Alexa Fluor 488 donkey anti-rabbit IgG and Alexa Fluor 555 donkey anti-mouse IgG (Molecular Probes/Invitrogen) were then applied at 1:500 each in PBS for 45 minutes, followed by three PBS washes for 5 minutes.

Finally, the slides were incubated in ToPro-3 iodide (Molecular Probes/Invitrogen) at 1:2000 in PBS for 20 minutes for nuclear staining and then washed with PBS for 5 minutes twice. The Slowfade Gold antifade reagent (Invitrogen) was used for the mounting of the slides. Images were acquired with a Zeiss 510 confocal microscope (Carl Zeiss MicroImaging, Thronwood, NY) using 40×/1.30 objective with oil immersion.

**Transmission Electron Microscopy**

Approximately 1-mm3 colon mucosa samples were fixed with 3% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.3), postfixed with 1% osmium tetroxide,
and stained en bloc with 1% uranyl acetate. Samples were dehydrated in increasing concentrations of ethanol, infiltrated, embedded in Epon medium, and polymerized at 70°C for 2 days. Ultrathin sections were stained with uranyl acetate and lead citrate and were examined in a JEM 1010 transmission electron microscope (JEOL USA Inc., Peabody, MA). Digital images were obtained by using AMT Image System (Advanced Microscopy Techniques, Danvers, MA).

**BrdU Labeling**

NHERF1 wild-type and mutant mice were injected intraperitoneally with 0.1 ml/10 g body weight of BrdU (Invitrogen), and sacrificed 2 hours later. Organs were harvested, fixed in 10% formalin overnight, and processed for IHC with the Animal Research Kit (Dako, Carpinteria, CA).

**Plasmids, Transfections, and Protein Analysis**

Human cDNAs for full-length NHERF1 and for the PDZ1 and PDZ2 domains were previously described [13]. They were inserted in frame with a Myc tag in the pcDNA3 vector. FLAG-tagged YAP wild type and YAP-S127A mutant in pCMV vector were kind gifts of Dr. K. Bhat, MD Anderson Cancer Center. The control short hairpin RNA (shRNA) and NHERF1 shRNA-1 and 4 in pSIREN-RetroQ vector and the protocol for retroviral infection of human Caco-2 CRC cells were previously described [14]. The protocols for 293T human embryonic kidney cells transfection, cell lysis, immunoprecipitation, and Western blot were previously described [23]. The cell lysis and Western blot analysis of human frozen samples were performed as described [14]. Subcellular fractionation in nuclear, cytoplasmic, and membrane compartments was described [16]. Antibodies for Western blot were obtained from the following: Myc: Invitrogen; FLAG (M2): Sigma-Aldrich, St. Louis, MO; YAP (4912) and P-YAP (4911); Cell Signaling Technology; PTEN (A2B1), PARP (H-250), and GAPDH (0411); Santa Cruz Biotechnology; E-cadherin: BD Biosciences; and villin: Chemicon/Millipore, Temecula, CA.

**Statistics**

All numerical data were examined for normality of distribution and expressed as means ± standard error of the mean (SEM) unless mentioned otherwise. Unpaired two-tailed t test with or without Welch correction for variances significantly different was used to analyze the differences between groups. Kaplan-Meier survival analysis using Gehan-Breslow-Wilcoxon test was plotted with the GraphPad Prism program (GraphPad Software, La Jolla, CA). The densitometric analysis was performed with Image) program (National Institutes of Health, Bethesda, MD). Data are representative of at least two or three independent experiments with similar results. Statistical significance was considered for P < .05.

**Results**

**Altered Intestinal Length and Cell Composition in NHERF1 Deficient Mice**

NHERF1 deficiency leads to morphological alterations of some specialized epithelia or epithelial-like linings in the body, including mammary gland, coheia, and ependyma, resulting in dysfunction [20,24,25]. We have previously shown disruption of the brush border membrane and increase of goblet cells in the small intestine of NHERF1-deficient mice [19]. To better assess the intestinal defects, we analyzed the intestine in cohorts of approximately 19.5-month-old NHERF1+/− and NHERF1−/− littermates. Inspection showed significantly longer small intestine and colon in both male and female NHERF1+/− mice (Figure 2A). Complete histopathologic assessment of these mice showed a series of lesions associated with age (Supplementary Table 1). Of these, malignancies such as lymphoma and histiocytic sarcoma appeared equally distributed in NHERF1+/− and NHERF1−/− mice. Lymphoid hyperplasia was present in various locations in the majority of mice but appeared more extensive in NHERF1−/− mice. Nephropathies, such as glomerulonephritis and lymphocytic tubulointestinal nephritis, and lymphocytic sialo- and dacyroadenitis were lesions much more commonly found in NHERF1−/− mice (Supplementary Table 1).

To examine whether the intestinal defects are developmental or adaptative, we performed a prospective analysis in cohorts of NHERF1+/− and NHERF1−/−ibred mice sacrificed at 6, 12 and 24 weeks. Of note is that a large proportion of NHERF1−/− mice have small weight at 3 weeks of age because of maternal lactation deficit [20]; therefore, the analysis of the intestine started at 6 weeks of age, when NHERF1+/− and NHERF1−/− mice showed comparable weights. The small intestine and colon were separately measured for males and females, and the length was expressed as length index, the ratio of absolute length to the body mass (Figure 1B). In comparison to control NHERF1+/− mice, the small intestine length index was significantly higher for NHERF1−/− male mice for all age groups and for NHERF1−/− female mice for two of three age groups (Figure 1B, upper graphs). For 12-week-old females, a trend was present, but the difference was not statistically significant. Similar results were found for the colon length index (Figure 1B, middle graphs). The body mass of NHERF1+/− and NHERF1−/− mice was equivalent at 6 weeks of age for both genders and at 12 and 24 weeks for female mice (Figure 1B, lower graphs). NHERF1−/− males showed a steeper growth curve compared to NHERF1−/− counterparts at 12 and 24 weeks of age, with statistically significant higher body masses at these time points. However, old males had equivalent body masses, whereas the weight distribution for old females, especially wild type, was scattered (Figure 1A).

To find out why NHERF1-deficient mice have longer intestines than their wild-type counterparts, we examined the expression of NHERF1 in the intestine. While it is well known that NHERF1 is expressed in IECs (Figure 2A, yellow arrowhead) [26,27], it also has high apical PM expression in the mesothelial cells of the serosa as well (Figure 2A, arrow) [26]. IECs result from the proliferation of intestinal stem cells through transit-amplifying/progenitor cells in the crypts followed by terminal differentiation into four mature populations: absorptive cells, goblet cells, Paneth cells, and neuroendocrine cells [7]. The proliferation of progenitor cells was measured by BrdU incorporation and was equivalent in the crypts of NHERF1+/− and NHERF1−/− mice (Figure 2B). As control, splenic cells showed higher proliferation in NHERF1−/− mice. However, the localization of the NHERF1−/− BrdU-labeled progenitors appeared shifted to upper positions in the crypts. By matching the number of BrdU-positive cells with the cell position from the crypt bottom, we confirmed this observation (Figure 2B). This implied that there is a cell population that displaces upward the progenitor cells in the crypts. The examination of H&E small intestine sections revealed increased numbers of Paneth cells in the NHERF1−/− crypts (Figure 2C, arrow). Staining for lysozyme that specifically identifies secretory Paneth cells in crypts and with Alcian blue that highlights goblet cells showed increased numbers of both types of these secretory IECs in NHERF1−/− intestine.
C}, suggesting that NHERF1 controls the step differentiation of progenitor cells into the various populations of IECs. We have previously shown ultrastructural defects of the brush border membrane of absorptive IECs in the ileum[19]. Ultrastructural analysis of the colon brush border revealed shorter microvilli of the $\text{NHERF1}^{-/-}$ colonocytes, with a length of approximately 67% the length of wild-type microvilli (Figure 2D), confirming previous independent findings in colon[28]. These results suggest that the alterations of IECs might be at least in part responsible for the increased intestine length of $\text{NHERF1}^{-/-}$ mice.

Decreased Survival and Increased Tumor Load in NHERF1 Deficient APC Mutant Mice

Pathways involved in tissue morphogenesis often play roles in tumorigenesis as well. One such pathway is the Wnt-APC-$\beta$-catenin, which is the key pathway involved in both morphogenesis and tumorigenesis in the intestine[29]. We have previously demonstrated that NHERF1 downregulation induces tumorigenic effects in human intestinal cells in 2D and 3D tissue models [14,17]. Because we found that NHERF1 is involved in intestinal morphogenesis, we explored the possibility that it may act as a tumor suppressor in vivo as well. $\text{NHERF1}^{-/-}$ mice were crossed to $\text{ApcMin/}^+/+$ mice, and the offspring carrying the Min allele were selected for survival analysis (Figure 3A). Double-mutant $\text{ApcMin/}^+/+$ $\text{NHERF1}^{-/-}$ mice had a median survival of 19 weeks, markedly shorter than the $\text{ApcMin/}^+/+$ counterparts. Interestingly, no significant difference was observed between the double-heterozygous $\text{ApcMin/}^+/+$ $\text{NHERF1}^+/-$ mice and the $\text{ApcMin/}^+/+$ mice, and their median survivals were 28 and 29 weeks, respectively. This suggests that one wild-type $\text{NHERF1}$ allele is sufficient to provide adequate functional levels of NHERF1.

To study tumor development, new cohorts of $\text{ApcMin/}^+/+$ and $\text{ApcMin/}^+/+$ $\text{NHERF1}^{-/-}$ mice were sacrificed at 16 weeks (Figure 3B). This time point that closely precedes the median survival of double-mutant $\text{ApcMin/}^+/+$ $\text{NHERF1}^{-/-}$ mice was chosen based also on a previous study showing no increase in the number of tumors detected in $\text{ApcMin/}^+/+$ mice after 80 days of age[30]. At 16 weeks, $\text{ApcMin/}^+/+$ $\text{NHERF1}^{-/-}$ mice had lower body mass than $\text{ApcMin/}^+/+$ $\text{NHERF1}^+/-$ mice ($P = .05$), most likely because of more advanced disease (Figure 3B). An enhanced production of IL-6 has been associated to cachexia in $\text{ApcMin/}^+/+$ mice[31]. All $\text{ApcMin/}^+/+$ mice showed signs of anemia, such as pale limbs and compensatorily enlarged spleens with increased extramedullary hematopoiesis (Figure S1). In both humans with CRC and in $\text{ApcMin/}^+/+$ mice, chronic bleeding due to a compromised intestinal epithelial lining leads to...
severe anemia, which most likely precipitates death in mice \[32\]. The small intestine and colon were dissected and prepared as Swiss roll for histological examination (Figure S2). Neoplastic lesions, including adenomas (diameter $\geq 1$ mm) and microadenomas, were counted and the highest tumor density scored (Figures S3-S4). The double-mutant $\text{Apc}^{\text{Min}}+/\text{NHERF1}^{-/-}$ mice had a significantly higher tumor density in the small intestine than $\text{Apc}^{\text{Min}}+/\text{NHERF1}^{+/+}$ mice (Figures 3, B and C and S5). We noticed a tendency of developing more tumors in $\text{Apc}^{\text{Min}}$/ females than in males, which was even more pronounced in the double-mutant mice, with statistically significant differences of 34% and 73%, respectively (Figures 3B and S5). The regional tumor distribution was similar for both genotypes, with an increasing gradient along its length resulting in consistently higher polyp numbers in the distal segment than in the rest of the intestine (Figure 3D). This distribution in C57BL/6 $\text{Apc}^{\text{Min}}/+$ mice is consistent with previous studies \[33,34\]. The tumorigenesis in the colon was much less developed than in the intestine, with only few or no polyps present, and a significant difference between $\text{Apc}^{\text{Min}}+/\text{NHERF1}^{-/-}$ and $\text{Apc}^{\text{Min}}+/\text{NHERF1}^{+/+}$ mice was noted only for females (Figure 3B).

All adenomas (diameter $\geq 1$ mm) were measured on each section level, and the highest measurement for a single tumor was scored (Figure S4). $\text{Apc}^{\text{Min}}+/\text{NHERF1}^{-/-}$ mice had double the number of adenomas of $\text{Apc}^{\text{Min}}+/\text{NHERF1}^{+/+}$ mice (Figure 3E and Table S2). The partition of adenomas on gender showed only slight preponderance in double-mutant females (Figure S5). Adenomas were segregated also in four consecutive size categories (Figure 3F). A

---

**Figure 2.** Intestinal defects in $\text{NHERF1}^{-/-}$ mice. (A) IF with $\text{NHERF1}$ antibody and DAPI for highlighting nuclei in $\text{NHERF1}^{-/-}$ and $\text{NHERF1}^{+/+}$ mice shows high $\text{NHERF1}$ apical PM expression in intestinal epithelium (yellow arrowhead) and in the mesothelial lining of the serosa (arrow). (B) BrdU incorporation in 6-week-old $\text{NHERF1}^{-/-}$ and $\text{NHERF1}^{+/+}$ female littermates showing similar numbers of BrdU+ cells in both genotypes and upper displacement of the BrdU+ progenitor cells in $\text{NHERF1}^{-/-}$ crypts (right graph). Data are means ± SEM from 50 crypts. The cell position 0 was assigned for the bottom-most cell of every counted crypt. In contrast, $\text{NHERF1}^{-/-}$ spleen BrdU+ counts show significantly enhanced proliferation. (C) H&E, lysozyme IHC for Paneth cells, and Alcian blue special stain for goblet cells of ileum sections show higher numbers of Paneth (arrows in H&E) and goblet cells in $\text{NHERF1}^{-/-}$ versus $\text{NHERF1}^{+/+}$ mice. (D) Transmission electron microscopy (TEM) shows blunted microvilli in $\text{NHERF1}^{-/-}$ colon epithelium.
A higher number of adenomas were noted in all the categories for the double-mutant ApcMin/+NHERF1−/− mice, irrespective of gender. Strikingly, the largest tumors were on average seven times more numerous in ApcMin/+NHERF1−/− mice than in ApcMin/+NHERF1+/+ mice (Figure 3F, lower graph and Table S2). Interestingly, the distribution of these large adenomas (>2.5 mm) was in the proximal and middle segments of the small intestine and in the colon, and attained very large sizes in double-mutant ApcMin/+NHERF1−/− mice, especially in the colon (Figure 3F, right graph). In ApcMin/+NHERF1+/+ mice, large adenomas were seen only in the proximal segment of the intestine.
small intestine. Concurrently, the regional distribution of adenomas in these mice was blunted, indicating that most of the tumors were small at 16 weeks of age (Figure 3D). In contrast, the regional distribution of adenomas in Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> mice respected the incremental gradient along the intestine, suggesting an increased tumor growth rate that parallels the rate of tumor initiation in these mice (Figure 3D). The histology of the tumors was that of tubular adenoma with or without high-grade dysplasia (Figure S6). Occasional gland herniation was noted at the base of the polypl but without frank invasion. Metastatic workup of liver and lung in four Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> animals examined at the time of death did not find evidence of metastatic disease.

Overall, this analysis showed that the tumor load, including both the tumor density and tumor size, was significantly higher for both genders of the Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> mice (Supplementary Table 2 and Figure S5), explaining the shorter survival of these animals.

**Increased β-Catenin, YAP and Cyclin D1 Nuclear Localization in Tumors from NHERF1 Deficient Mice**

The finding of larger adenomas in Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> than in Apc<sup>Min</sup>−/− NHERF1<sup>+/−</sup> mice at a given time point suggested a higher growth rate for Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> tumors. To investigate the tumor suppressor function of NHERF1 on adenoma growth, we first examined the expression levels of NHERF1 in tumors from Apc<sup>Min</sup>−/− NHERF1<sup>+/−</sup> mice. Compared to normal surrounding mucosa, both microadenomas and macroadenomas had decreased NHERF1 expression levels by IF and IHC (Figures 4A and S7). This result suggests a growth suppressor role of NHERF1 and is similar to results from human CRC, where NHERF1 loss from the apical PM occurs from early adenoma stage [14].

We and others have shown that NHERF1 controls tumor growth through interactions with tumor suppressor or oncogenic proteins [35] (Figure 4B). More specifically, NHERF1 suppresses the PI3 kinase-Akt pathway by interacting with PTEN tumor suppressor [13], and the Wnt-β-catenin pathway by interacting with β-catenin and Frizzled family members [12,16,36]. Recently, links between the Wnt-β-catenin pathway and YAP, the downstream effector of the Hippo pathway, have been revealed [11].

NHERF1 has been previously shown to interact with YAP [37], but the implications of this interaction for tumor growth have not been studied. We confirmed that NHERF1 and YAP co-immunoprecipitate and that this interaction for tumor growth have not been studied. We confirmed the loss of apical polarity in NHERF1-depleted cells by the downregulation of villin, a protein involved in the structural assembly of microvilli (Figure 4D). In NHERF1-depleted cells, phosphorylated YAP was decreased in the cytoplasmic compartment, whereas unphosphorylated YAP was increased in the nuclear compartment (Figure 4D), consistent with the translocation of unphosphorylated YAP to the nucleus in the absence of NHERF1.

In human CRC cells, depletion of NHERF1 from the apical PM also results in β-catenin translocation to the nucleus, presumably due to polarity loss and epithelial to mesenchymal transition [14,17]. As previously noted in Apc<sup>Min</sup>−/− mice, the expression of β-catenin increased in tumors compared to adjacent normal mucosa [38], and we also observed this pattern regardless of the NHERF1 genotype. However, in Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> mice, tumors showed higher expression of β-catenin, including nuclear β-catenin (Figure 4E).

In normal intestine, both phosphorylated YAP and total YAP were expressed in the crypt epithelium and not in the villi (Figure S8A). The aberrant crypt foci exhibited similar expression levels as the surrounding crypts (Figure S8A). Whereas YAP had nuclear expression in some neoplastic cells of tumors from Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> mice (Figure 4E), phosphorylated YAP was mostly restricted to the cytoplasmic cell compartment of these tumors where it appeared decreased (Figure S8B). The findings from Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> tumors were similar to those from Caco-2 NHERF1-depleted cells (Figure 4, D and E), suggesting that NHERF1 controls the nuclear translocation of YAP in vivo and in vitro.

Strikingly, cyclin D1, a downstream effector of the Wnt/β-catenin pathway in CRC [8] but also of the Hippo-YAP pathway [39], had prominent nuclear expression in the neoplastic glands from Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> tumors and not in the normal mucosa (Figure 4E). The nuclear expression of cyclin D1 from Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> tumors was much higher and diffuse than that seen in Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> tumors (Figure 4E), explaining the faster growth rate of the Apc<sup>Min</sup>−/− NHERF1<sup>−/−</sup> tumors. Although NHERF1 is a positive regulator of PTEN tumor suppressor [13] and PTEN suppresses cyclin D1 levels [40], we could not find elevated phosphorylated Akt by IHC in the tumors examined (not shown).

**Analysis of YAP and Phosphorylated YAP Expression in Matched Normal-Adenoma-Carcinoma Specimens of Human CRC**

We have previously shown in matched normal-adenoma-carcinoma specimens that NHERF1 membrane expression is lost early in adenoma and that loss or cytoplasmic overexpression is present in carcinoma [14]. Examination of the expression levels of phosphorylated YAP in the same series of frozen specimens by Western blot showed a sharp drop from early initial adenoma stages (Figure 5A). Total YAP expression levels decreased much less and more gradually in the sequence normal-adenoma-carcinoma, resulting in a relative decrease of phosphorylated YAP as compared to total YAP (Figure 5A, upper graph). IHC of resection specimens with normal, adenoma, and carcinoma histology on the same slide showed a marked increase of YAP nuclear staining from normal to adenoma and carcinoma stages, with moderate and prominent nuclear staining in adenoma and carcinoma, respectively (Figure 5B, lower panels). This suggested activation of the transcriptional growth program regulated by YAP. IHC with P-YAP antibody showed the presence of phosphorylated YAP in the cytoplasm of cells in normal, adenoma, and carcinoma tissues with similar levels in adenoma and carcinoma (Figure 5B, middle panels). Occasional moderate nuclear staining was noted in adenoma and carcinoma. In some cases, the levels of phosphorylated YAP appeared lower in normal epithelial cells, as in the case depicted in Figure 5B. Interestingly, the smooth muscle of muscularis mucosae and of the small arteries in the submucosa expressed phosphorylated YAP in the cytoplasm (Figure 5B, arrows). As these components are usually present in a normal mucosal biopsy, the high levels of phosphorylated YAP noted in the normal
**Figure 4.** NHERF1 deficiency promotes nuclear localization of β-catenin, YAP, and cyclin D1. (A) IF analysis of Apc\textsuperscript{Min/+} NHERF1\textsuperscript{+/+} normal mucosa and adenomas with antibodies indicated on the left and TOPRO-3 highlighting nuclei shows strong NHERF1 expression at the apical PM of enterocytes from normal mucosa and loss of expression in adenoma. (B) Schematic domain structure of NHERF1 showing interactions with selected ligands involved in tumor growth and the pathways they control. EB, ERM-binding region. (C) Co-immunoprecipitation (IP) of proteins from total lysates (TL) of 293T cells coexpressing FLAG-tagged YAP wild type or YAP-S127A phosphorylation-deficient mutant and Myc-tagged NHERF1 full length and separate PDZ domains (red arrowheads). HC, heavy chain. V, YAP plasmid vector. Note interaction between NHERF1 full length or PDZ2 with either YAP wild type or S127A mutant. (D) Subcellular fractionation in nuclear (Nuc), cytoplasmic (Cyt), and membrane (Memb) fractions of Caco-2 CRC cells infected with either shRNA vector (shV) or shRNA-1 NHERF1 (shRF1). Proteins from total cell lysates (TL) and subcellular fractions were loaded at 20 μg per lane. PARP, PTEN, and E-cadherin were used as nuclear, cytoplasmic, and membrane fractionation markers, respectively. By using this procedure, it is known that cross contamination may occur between the nuclear fraction and membrane components, whereas the cytoplasmic fraction is pure. Normalized phosphorylated YAP (P-YAP) to YAP expression in total lysates and normalized nuclear YAP to PARP expression are represented as mean ± SD in control and NHERF1 knockdown Caco-2 cells. *P < .05. E. IHC with β-catenin, YAP, and cyclin D1 antibodies shows higher expression of these proteins in Apc\textsuperscript{Min/+} NHERF1\textsuperscript{−/−} tumors compared to control. Nuclear expression is elevated for β-catenin and YAP in Apc\textsuperscript{Min/+} NHERF1\textsuperscript{−/−} tumors, and very prominent for cyclin D1.
tissue from the frozen specimens (Figure 5A) may in part be due to the smooth muscle cells. However, normalization of these levels to total YAP, also present in the same smooth muscle cell compartments (Figure 5B, arrows), most likely reflected the fraction of YAP that is phosphorylated overall. Altogether, the relative decrease of phosphorylated YAP and the increase of YAP nuclear expression in human CRC samples were in concordance with the observations from ApemMin/+NHERF1−/− mice.

**Discussion**

In this study, we examined the effect of NHERF1 deficiency on intestinal tumorigenesis in order to explore the significance of the loss of NHERF1 that we have reported in human CRC [14]. NHERF1 deficiency as a single hit in mice does not lead to intestinal polyposis. Old mice have increased lymphoid proliferation in many organs, including in the gut-associated lymphoid tissue, and NHERF1 deficiency increases the intensity of this process. NHERF1-deficient

---

**Figure 5.** Progressive changes of YAP phosphorylation and expression in CRC. (A) Western blot with phosphorylated YAP (S127) (P-YAP) and total YAP antibodies of proteins (20 μg) from whole tissue lysates from frozen matched sets of normal (N), adenoma (A), and carcinoma (C) samples shows decrease of phosphorylated YAP from adenoma stages in the progression of CRC. AJCC stage is indicated for each case. The filters were first probed with P-YAP antibody, stripped, and probed with YAP antibody. Both antibodies recognized a band corresponding to the YAP65 isoform that contains only one WW domain and is expressed in nuclear (Nuc) and cytoplasmic (Cyt) extracts of mouse embryonic fibroblasts (MEFs). A separate run was performed for control GAPDH. Normalized phosphorylated YAP (P-YAP) to YAP expression and normalized YAP to GAPDH expression are represented as mean ± SD. *P < .01 versus normal tissue. (B) IHC analysis with P-YAP and YAP antibodies of resection specimens containing adjacent areas of normal mucosa, adenoma, and carcinoma on the same slide shows expression of both forms in the normal epithelial cells but also in the smooth muscle cells of the muscularis mucosae and arteries media (arrows). P-YAP is mostly confined to the cytoplasmic compartment, and YAP stains the cytoplasm and some nuclei. Note increased YAP staining of both subcellular compartments in carcinoma.
mice have nevertheless morphological defects of both small intestine and colon, including attenuated brush border of absorptive IECs, increased numbers of secretory IECs, and significantly increased length. The latter reaches 24% increase for aged females (at 84% of wild-type body mass) and 15% increase for aged males (at 103% of wild-type body mass) in the small intestine, and 11% increase for both genders in the colon. Smaller but significant differences are also detected in very young mice, arguing for a combination of developmental and adaptive determining factors. NHERF1 interacts with and regulates the activity of ion exchangers and channels, such as NHE3 and CFTR [28,41–43] that are expressed in the intestinal brush border. NHE3-deficient mice have apoptotic defects and compensatory enlarged small intestine and colon, although by distension rather than by increased segmental length [44]. CFTR mutant mice have increased numbers of goblet cells in the ileum similar to NHERF1-deficient mice, and mildly increased small intestine length (by 10%) [45,46]. To our knowledge, the increase in intestinal length in the NHERF1-deficient mice is the highest reported, being most likely due to contributions from an altered mucous and possibly serosa.

As this is the first demonstration of the tumor suppressor role of NHERF1 in vivo, we undertook a thorough analysis of the tumorigenesis in the intestine. NHERF1 deficiency in the context of the APC mutation in ApcMin+/− mice leads to drastic shortening of the survival of double-mutant mice due to significantly increased tumor load. The complete absence of NHERF1 expression is required for tumorigenesis, as heterozygous NHERF1 mice do not show a different phenotype from NHERF1 wild-type mice. One intriguing observation in our cohorts was the difference in tumorigenesis between ApcMin+/− male and female mice. The tumor density was increased in female mice of both genotypes, whereas adenomas developed at a similar rate in both genders in ApcMin+/− mice and yet again with female predominance in ApcMin+/− NHERF1−/− double-mutant mice. One correlation is the regulation of NHERF1 expression by estrogen receptor [47] and its variation in rodent developmental and adaptive determining factors. NHERF1 interacts detected in very young mice, arguing for a combination of wild-type body mass) in the small intestine, and 11% increase for matched controls but fail to develop adenomas, defined as lesions with diameter > 1 mm, as in our study [51].

Analysis of possible pathways upstream of cyclin D1 upregulation in ApcMin+/− NHERF1−/− tumors showed elevated levels of cytoplasmic and nuclear β-catenin and elevated levels of nuclear YAP. The involvement of these pathways downstream of NHERF1 may explain not only the intestinal oncogenesis from NHERF1-deficient mice but perhaps some of the morphological defects, such as increased numbers of secretory cells. YAP has been recently shown to promote the differentiation of intestinal stem cells into goblet cells [52], and Wnt overactivation by APC loss leads to overproduction of Paneth cells [53]. Interestingly, CFTR mutant mice that share some similar morphological intestinal defects as NHERF1−/− mice have also increased intestinal tumorigenesis on an ApcMin+/− background that may be due to increased Wnt-β-catenin pathway [54].

Mechanistically, NHERF1 interacts through its PDZ domain with both β-catenin and YAP [12,37], and a direct interaction between NHERF1 and some members of the Fizzled family has also been documented [36] (Figure 4B). We have previously shown that NHERF1 contributes to the stabilization of E-cadherin–β-catenin complexes at the PM in mouse embryonic fibroblasts and also human CRC cells [14,16]. NHERF1 deficiency leads to E-cadherin and β-catenin drop from the PM, increase in cytoplasmic and nuclear β-catenin, and β-catenin promoter transactivation [16]. The interaction between NHERF1 and YAP has been involved in the compartmentalization of YAP at the apical PM in polarized airway epithelial cells [37]. We have shown here that NHERF1 deficiency, either by shRNA knockdown in CRC cells or by gene knockout in mice, leads to accumulation of unphosphorylated active YAP that most likely contributes to tumorigenesis either by inducing target genes of the transcriptional YAP/TAZ-TEAD complex or by entering in a transcriptional complex containing β-catenin [11] (Figure 4B). The nuclear expression of unphosphorylated YAP was also confirmed in human CRC samples. Although YAP has been found at the apical PM in airway cells [37], it is mainly distributed in the cytoplasm of normal crypt cells in the intestine. Whether the mechanism of YAP nuclear translocation involves direct interaction between the cytoplasmic fractions of NHERF1 and YAP with sequestration of the unphosphorylated YAP fraction in the cytoplasm or a more indirect signaling involving YAP dephosphorylation [55] is unknown at the present time.

In conclusion, we show here that NHERF1 loss from the PM is oncogenic in vivo through its influence on Wnt-APC-β-catenin and Hippo-YAP pathways. Further in vivo studies are required to extend this role to other malignancies dependent of the Wnt-β-catenin pathway and to dissect the functions of NHERF1 in other subcellular locations. The understanding of the function of NHERF1 will trigger the refinement of the ongoing therapeutic efforts for modulating its activity [56,57].

Acknowledgements
The authors thank Erica Kreimann and Clifton Stephens for help with the analysis of aged mice and Kenneth Dunner for help with electron microscopy.

This work was supported by the National Cancer Institute CA107201 grant and MD Anderson Cancer Center G. S. Hogan Gastrointestinal Research Fund to M. M. G. Animal breeding and tissue processing were partly supported by the National Cancer Institute CA16672 grant and by the National Institutes of Health Public Health Service grant P30-DK56338 (funding the Texas Medical Center Digestive Disease Center). respectively.
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.neo.2016.07.003.

References

[1] Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, and Thun MJ (2005). Cancer statistics, 2005. CA Cancer J Clin 55, 10–30.
[2] Brenner H, Kloor M, and Pox CP (2014). Colorectal cancer. Lancet 383, 1490–1502.
[3] Vogelstein B and Kinzler KW (2004). Cancer genes and the pathways they control. Nat Med 10, 789–799.
[4] Gregorieff A, Pinto D, Begthel H, Destree O, Kielman M, and Clevers H (2005). Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin independently of Zn2+/GSK3beta activity. Dev Cell 4, 407–418.
[5] Cronvier C, Stamatakis D, and Lewis J (2006). Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet 7, 349–359.
[6] He X, Semenov M, Tamai K, and Zeng X (2004). LDL receptor
[7] Shibata T, Chuma M, Kokubu A, Sakamoto M, and Hirohashi S (2003). PTEN, a Merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-negative breast carcinomas. Am J Pathol 158, 57–62.
[8] Tetsu O and McCormick F (1999). Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422–426.
[9] Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummings JM, DeLong L, Silliman N, Ptak J, Szabo S, and Willson JK, et al (2005). Colorectal cancer: mutations in a signalling pathway. Nature 436, 792.
[10] Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, and Guzzardo V, et al (2014). YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 158, 157–170.
[11] Hansen CG, Meroiishi T, and Guan KL (2015). YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol 25, 499–513.
[12] Shibata T, Chuma M, Kokubu A, Sakamoto M, and Hirohashi S (2003). EBPs, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology 38, 178–186.
[13] Takahashi Y, Morales FC, Kreimann EL, and Georgescu MM (2006). PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 25, 910–920.
[14] Hayashi Y, Molina JR, Hamilton SR, and Georgescu MM (2010). NHERF1/EBP50 is a new marker in colorectal cancer. Neoplasia 12, 1013–1022.
[15] Mallette A, Silvestris N, Paradiso A, Mattioli E, Simone G, and Mangia A (2012). Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype. Exp Mol Pathol 92, 296–303.
[16] Kreimann EL, Morales FC, de Orbeta-Cruz J, Takahashi Y, Adams H, Liu TJ, McCrea PD, and Georgescu MM (2007). Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function. Oncogene 26, 5290–5299.
[17] Georgescu MM, Core G, Agarwal NK, and White III CL (2014). NHERF1/EBP50 controls morphogenesis of 3D colonic glands by stabilizing PTEN and ezrin-radixin-moesin proteins at the apical membrane. Neoplasia 16, 365–374.
[18] McCarty AE, Vickaryous NK, and Silver A (2008). Apc mice: models, modifiers and mutants. Pathol Res Pract 204, 479–490.
[19] Morales FC, Takahashi Y, Kreimann EL, and Georgescu MM (2004). Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 organizes ERM proteins at the apical membrane of polarized epithelia. Proc Natl Acad Sci U S A 101, 17705–17710.
[20] Morales FC, Hayashi Y, van Pelt CS, and Georgescu MM (2012). NHERF1/EBP50 controls ligation by establishing basal membrane polarity complexes with prolactin receptor. Cell Death Dis 3:e391.
[21] Boivin GP, Washington K, Yang K, Ward JM, Prettow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, and Dove WF, et al (2003). Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124, 762–777.
[43] Weinman EJ, Steplock D, Wang Y, and Shenolikar S (1995). Characterization of a protein cofactor that mediates protein kinase A regulation of the renal brush border membrane Na(+)–H(+) exchanger. J Clin Invest 95, 2143–2149.

[44] Schultheis PJ, Clarke LL, Meneton P, Miller ML, Soleimani M, Gaweis LR, Riddle TM, Duffy JJ, Doetschman T, and Wang T, et al (1998). Renal and intestinal absorptive defects in mice lacking the NHE3 Na(+)/H(+) exchanger. Nat Genet 19, 282–285.

[45] Ohlsson L, Hjelte L, Huhn M, Scholte BJ, Wilke M, Flodstrom-Tullberg M, and Nilsson A (2008). Expression of intestinal and lung alkaline sphingomyelinase and neutral ceramidase in cystic fibrosis F508del transgenic mice. J Pediatr Gastroenterol Nutr 47, 547–554.

[46] Wilke M, Buijs-Offerman RM, Aarbiou J, Colledge WH, Sheppard DN, Touqui L, Bot A, Jorna H, de Jonge HR, and Scholte BJ (2011). Mouse models of cystic fibrosis phenotypic analysis and research applications. J Cyst Fibros 10(Suppl. 2), S152–S171.

[47] Ediger TR, Kraus WL, Weinman EJ, and Katzenellenbogen BS (1999). Estrogen receptor regulation of the Na(+)/H(+) exchange regulatory factor. Endocrinology 140, 2976–2982.

[48] Cuello-Carrion FD, Troncoso M, Guinazu E, Valdez SR, Fanelli MA, Ciocca DR, and Kreimann EL (2010). Estrogens regulate the expression of NHERF1 in normal colon during the reproductive cycle of Wistar rats. Histochem Cell Biol 134, 623–630.

[49] Yoshida M, Zhao L, Grigoryan G, Shim H, He P, and Yun CC (2016). Deletion of Na(+)/H(+) exchanger regulatory factor 2 represses colon cancer progress by suppression of Stat3 and CD24. Am J Physiol Gastrointest Liver Physiol 310, G586–G598.

[50] Taketo MM and Edelmann W (2009). Mouse models of colon cancer. Gastroenterology 136, 780–798.

[51] Sansom OJ, Reed KR, van de Wetering M, Muncan V, Winton DJ, Clevers H, and Clarke AR (2005). Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine. J Biol Chem 280, 28463–28467.

[52] Imao M, Ebisuya M, and Nishida E (2015). Dual role of YAP and TAZ in renewal of the intestinal epithelium. Nat Cell Biol 17, 7–19.

[53] Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, Battle E, Simon-Assmann P, Clevers H, and Nathke IS, et al (2004). Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 18, 1385–1390.

[54] Than BL, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abraham J, Schumann A, and Luzcak T, et al (2016). CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene.

[55] Kremer KN, Dudakov A, Hess AD, Smith BD, Karp JE, Kaufmann SH, Westendorf JJ, van Wijnen AJ, and Hedin KE (2015). Histone deacetylase inhibitors target the leukemic microenvironment by enhancing a Nherf1-protein phosphatase 1alpha-TAZ signaling pathway in osteoblasts. J Biol Chem 290, 29478–29492.

[56] Fitzpatrick JM, Pellegrini M, Cashing PR, and Mierke DF (2014). Small molecule inhibition of the Na(+)/H(+) exchange regulatory factor 1 and parathyroid hormone 1 receptor interaction. Biochemistry 53, 5916–5922.

[57] Mayaundari A, Ferreira AM, He L, Mahindroo N, Bashford D, and Fujii N (2008). Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains. Bioorg Med Chem Lett 18, 942–945.